CANF Can-Fite BioPharma
- 2.3599
- -0.00010.00%
Can-Fite BioPharma News
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer (related to financial reporting)
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | EFFECT: Others
Can-Fite BioPharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Can-Fite BioPharma | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 20-F: Registration statement / Annual report / Transition report
Can-Fite BioPharma | 6-K: Report of foreign private issuer (related to financial reporting)
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Can-Fite BioPharma | EFFECT: Others
Can-Fite BioPharma | CORRESP: CORRESP
Analysis
Price Target
No Data
